
Switching their focus to relapsed/refractory advanced clear cell renal cell carcinoma, key opinion leaders review treatment options in this setting.

Your AI-Trained Oncology Knowledge Connection!


Switching their focus to relapsed/refractory advanced clear cell renal cell carcinoma, key opinion leaders review treatment options in this setting.

Comprehensive insight to treatment options available in the second-line setting of advanced clear cell renal cell carcinoma.

Focused discussion on the rationale behind discontinuing (or continuing) immunotherapy for patients with advanced clear cell renal cell carcinoma.

Centering discussion on a patient scenario of advanced clear cell renal cell carcinoma, panelists reflect on how they would approach selecting first-line therapy.

Published: July 17th 2023 | Updated:

Published: July 10th 2023 | Updated:

Published: July 17th 2023 | Updated:

Published: July 10th 2023 | Updated: